Davidson Michael H. 4

What Happened
Michael H. Davidson, CEO of NewAmsterdam Pharma Co. N.V., exercised stock options and immediately sold 443,707 shares in an open-market transaction on March 2, 2026. The sale price was $33.25 per share, resulting in proceeds of $14,753,258. The underlying options had an exercise price of EUR 1.16392 per share.

Key Details

• Transaction date: March 2, 2026. Sale price: $33.25 per share. Total proceeds: $14,753,258.
• Transactions reported: option exercise/conversion (Form 4 code M) for 443,707 shares, followed by an open-market sale of the same 443,707 shares. A derivative disposition line ($0) reflects conversion of the option into shares.
• Exercise cost: EUR 1.16392 per share (≈ EUR 516k total for 443,707 shares, based on exercise price × shares).
• Shares owned after the transaction: not stated in the filing.
• Filing timeliness: Form 4 was filed the same day (March 2, 2026), indicating a timely report.
• Footnote: The option was a replacement grant dated Nov 22, 2022 (originally granted July 6, 2021). Vesting began Aug 1, 2021 (25% then, remaining monthly over three years), subject to continued service.

Context
This was a cashless exercise—Davidson exercised vested options and immediately sold all shares in the open market. For retail investors, sales by insiders are common and can be routine (e.g., to cover tax or exercise costs); they are not by themselves proof of company prospects. The filing documents the mechanics (exercise price, replacement grant and vesting schedule) but provides no additional explanation for the sale.